Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study.
dc.contributor.author | Schlesinger, Tobias | |
dc.contributor.author | Weißbrich, Benedikt | |
dc.contributor.author | Wedekink, Florian | |
dc.contributor.author | Notz, Quirin | |
dc.contributor.author | Herrmann, Johannes | |
dc.contributor.author | Krone, Manuel | |
dc.contributor.author | Sitter, Magdalena | |
dc.contributor.author | Schmid, Benedikt | |
dc.contributor.author | Kredel, Markus | |
dc.contributor.author | Stumpner, Jan | |
dc.contributor.author | Dölken, Lars | |
dc.contributor.author | Wischhusen, Jörg | |
dc.contributor.author | Kranke, Peter | |
dc.contributor.author | Meybohm, Patrick | |
dc.contributor.author | Lotz, Christopher | |
dc.date.accessioned | 2021-04-06T09:29:30Z | |
dc.date.available | 2021-04-06T09:29:30Z | |
dc.date.issued | 2020-11-24 | |
dc.identifier.citation | PLoS One. 2020 Nov 24;15(11):e0242917. doi: 10.1371/journal.pone.0242917. | en_US |
dc.identifier.pmid | 33232382 | |
dc.identifier.doi | 10.1371/journal.pone.0242917 | |
dc.identifier.uri | http://hdl.handle.net/10033/622820 | |
dc.description.abstract | Background: The viral load and tissue distribution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain important questions. The current study investigated SARS-CoV-2 viral load, biodistribution and anti-SARS-CoV-2 antibody formation in patients suffering from severe corona virus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS). Methods: This is a retrospective single-center study in 23 patients with COVID-19-induced ARDS. Data were collected within routine intensive care. SARS-CoV-2 viral load was assessed via reverse transcription quantitative polymerase chain reaction (RT-qPCR). Overall, 478 virology samples were taken. Anti-SARS-CoV-2-Spike-receptor binding domain (RBD) antibody detection of blood samples was performed with an enzyme-linked immunosorbent assay. Results: Most patients (91%) suffered from severe ARDS during ICU treatment with a 30-day mortality of 30%. None of the patients received antiviral treatment. Tracheal aspirates tested positive for SARS-CoV-2 in 100% of the cases, oropharyngeal swabs only in 77%. Blood samples were positive in 26% of the patients. No difference of viral load was found in tracheal or blood samples with regard to 30-day survival or disease severity. SARS-CoV-2 was never found in dialysate. Serologic testing revealed significantly lower concentrations of SARS-CoV-2 neutralizing IgM and IgA antibodies in survivors compared to non-survivors (p = 0.009). Conclusions: COVID-19 induced ARDS is accompanied by a high viral load of SARS-CoV-2 in tracheal aspirates, which remained detectable in the majority throughout intensive care treatment. Remarkably, SARS-CoV-2 RNA was never detected in dialysate even in patients with RNAemia. Viral load or the buildup of neutralizing antibodies was not associated with 30-day survival or disease severity. | en_US |
dc.language.iso | en | en_US |
dc.publisher | PLOS | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Biodistribution and serologic response in SARS-CoV-2 induced ARDS: A cohort study. | en_US |
dc.type | Article | en_US |
dc.identifier.eissn | 1932-6203 | |
dc.contributor.department | HIRI, Helmholtz-Institut für RNA-basierte Infektionsforschung, Josef-Shneider Strasse 2, 97080 Würzburg, Germany. | en_US |
dc.identifier.journal | PloS one | en_US |
dc.source.volume | 15 | |
dc.source.issue | 11 | |
dc.source.beginpage | e0242917 | |
dc.source.endpage | ||
refterms.dateFOA | 2021-04-06T09:29:30Z | |
dc.source.journaltitle | PloS one | |
dc.source.country | United States |